Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.

British journal of cancer·2016
Same author

Effect of screening for syphilis on the management of patients with cerebrovascular disease.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

COMPLETE INVERSION OF THE UTERUS RELIEVED BY ABDOMINAL OPERATION.

Canadian Medical Association journal·2010
Same author

Detection of lipoprotein(a) in intraparenchymal cerebral vessels: correlation with vascular pathology and clinical history.

Experimental and molecular pathology·2001
Same author

Gene expression of apolipoprotein(a) within the wall of human aorta and carotid arteries.

Atherosclerosis·2001
Same author

Effects of microphone type on acoustic measures of voice.

Journal of voice : official journal of the Voice Foundation·2001
Same journal

Relationship of serum nesfatin-1 levels with body mass index and c-reactive protein in patients presenting to the emergency department with epileptic seizures.

Postgraduate medicine·2026
Same journal

Clinical pharmacokinetics of colistimethate sodium and formed colistin in patients with renal impairment or on dialysis modalities: a systematic review and implications for precision dosing.

Postgraduate medicine·2026
Same journal

The role of type D personality in pregnancy symptom severity, functional limitations, and maternal ambivalence.

Postgraduate medicine·2026
Same journal

Operational and demographic predictors of leaving without being seen in a high-volume tertiary emergency department: a five-year case-control study.

Postgraduate medicine·2026
Same journal

Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.

Postgraduate medicine·2026
Same journal

Association between frailty and major chronic disease-free life expectancy: a large community-based longitudinal study.

Postgraduate medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Rizatriptan. Comparative trial results.

D G Jamieson1

  • 1Department of Neurology, Pennsylvania Hospital, Philadelphia, PA 19107, USA. dgjamieson@pahosp.com

Postgraduate Medicine
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Rizatriptan offers faster migraine relief than naratriptan and zolmitriptan, improving patients' ability to resume daily activities. This triptan drug provides rapid symptom control for acute migraine attacks.

Related Experiment Videos

Last Updated: Jun 21, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Four triptan-class drugs (sumatriptan, rizatriptan, naratriptan, zolmitriptan) are available for acute migraine treatment.
  • Comparative data can guide clinicians in selecting the most effective triptan medication.

Purpose of the Study:

  • To compare the efficacy and patient-reported outcomes of rizatriptan against naratriptan and zolmitriptan for acute migraine treatment.

Main Methods:

  • Analysis of data from two recent clinical trials comparing rizatriptan with naratriptan and zolmitriptan.
  • Evaluation of key endpoints including speed of pain relief, nausea reduction, and return to normal activities.

Main Results:

  • Rizatriptan demonstrated more rapid relief of headache pain compared to both naratriptan and zolmitriptan.
  • Associated nausea symptoms were also resolved more quickly with rizatriptan.
  • Patients treated with rizatriptan returned to normal daily activities significantly faster.

Conclusions:

  • Rizatriptan presents distinct advantages over naratriptan and zolmitriptan in managing acute migraine.
  • The faster onset of action and quicker return to function make rizatriptan a valuable option for patients experiencing debilitating migraine attacks.